Therapeutic Focus

Priavoid has built a CNS-focused pipeline that embodies highly innovative compounds at different stages of development.


Alzheimer’s disease (AD)

AD, also referred to simply as Alzheimer’s, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. AD is the cause of 60% to 70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss) and finally leads to death. To date, no treatments stop or reverse its progression, though some may temporarily improve symptoms. In 2015, there were approximately 29.8 million people worldwide with AD and resulted in about 1.1 million deaths. In developed countries, AD is a tremendous burden for health care systems and insurances.

Amyotrophic lateral sclerosis (ALS)

ALS, also known as Lou Gehrig’s disease and motor neurone disease (MND), is a specific disease that causes the death of neurons which control voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common. Descriptions of the disease date back to at least 1824 by Charles Bell. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. This results in difficulty speaking, swallowing, and eventually breathing. No cure for ALS is known. A medication called riluzole may extend life by about two to three months. ALS became well known worldwide when physicist Stephen Hawking, diagnosed in 1963 and expected to die within two years, became famous.


Tauopathies are a class of neurodegenerative diseases associated with the pathological aggregation of tau protein in neurofibrillary or gliofibrillary tangles in the human brain. Tangles are formed by hyperphosphorylation of a microtubule-associated protein known as tau, causing it to aggregate in an insoluble form. The precise mechanism of tangle formation is not completely understood, and it is still controversial as to whether tangles are a primary causative factor in the disease or play a more peripheral role. Neurofibrillary tangles were first described by Alois Alzheimer in one of his patients suffering from Alzheimer’s disease, which is considered a secondary tauopathy. Huntington’s disease is the most recently described tauopathy.

Huntington’s disease (HD)

HD, also known as Huntington’s chorea, is an inherited disorder that results in death of brain cells. The first likely description of the disease was in 1841 by Charles Oscar Waters. The condition was described in further detail in 1872 by George Huntington, after whom it is named. The earliest symptoms are often subtle problems with mood or mental abilities. A general lack of coordination and an unsteady gait often follow. As the disease advances, uncoordinated, jerky body movements become more apparent. There is no cure for HD. Full-time care is required in the later stages of the disease.


Parkinson’s disease (PD)

PD is a long-term degenerative disorder of the central nervous system that mainly affects the motor system. The disease is named after the English surgeon James Parkinson, who published the first detailed description in An Essay on the Shaking Palsy, in 1817. The symptoms generally come on slowly over time. Early in the disease, the most obvious are shaking, rigidity, slowness of movement, and difficulty with walking. Thinking and behavioral problems may also occur. Dementia becomes common in the advanced stages of the disease. There is no cure for Parkinson’s disease. Initial treatment is typically with the anti-Parkinson medication L-DOPA (levodopa), with dopamine agonists being used once levodopa becomes less effective. In 2015, PD affected 6.2 million people and resulted in about 117,400 deaths globally. People with parkinsonism who have increased the public’s awareness of the condition include actor Michael J. Fox, Olympic cyclist Davis Phinney, and late professional boxer Muhammad Ali.



Please use our contact form if you require any information.Pre-clinical and clinical trials are pursued at Priavoid for the development of drugs.

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help.

Select an option to continue

Your selection was saved!



To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set.

You can change your cookie setting here anytime: Privacy Policy. Legal Notice